LONDON, July 24, 2013 /PRNewswire/ --

On Tuesday, July 23, 2013, shares in biotechnology companies ended on a mixed note, tracking mix movements in the broader market. The major movers in the industry included Inovio Pharmaceuticals Inc. (NYSEMKT: INO), Sequenom Inc. (NASDAQ: SQNM), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX), and Optimer Pharmaceuticals Inc. (NASDAQ: OPTR). All these companies are tracked by AAAResearchReports.com. Free in-depth technical analysis on INO, SQNM, ONXX, and OPTR are currently available upon sign up at:

http://www.aaaresearchreports.com/register

Shares in Inovio Pharmaceuticals Inc. ended slightly higher on Tuesday, extending their gains from previous trading sessions. The company's shares oscillated between $1.25 and $1.29 before finishing the day 0.40% higher at $1.26. A total of 2.25 million shares were traded which is less than the daily average volume of 5.28 million. Inovio Pharmaceuticals' shares have gained 0.80% in the last three trading sessions as compared to a gain of 0.18% in the S&P 500. In the last one month, the stock has gained 81.29% as compared to a gain of 6.28% in the S&P 500. Sign up for free technical analysis on INO at:

http://www.AAAResearchReports.com/INO072413.pdf

Sequenom Inc.'s stock fell sharply on Tuesday, closing at $4.51, down 3.43% from previous trading session. The company's shares fluctuated between $4.50 and $4.69. A total of 1.65 million shares were traded which is below the daily average volume of 2.32 million. Despite Tuesday's sharp decline, the company's shares have gained 9.47% in the last one month, outperforming the S&P 500. Moreover, the stock is also trading above its 50-day and 200-day moving averages. Download free report on SQNM by registering at:

http://www.AAAResearchReports.com/SQNM072413.pdf

Shares in Onyx Pharmaceuticals Inc. edged higher on Tuesday, finishing at $130.31, up 0.82% from its previous closing price. The company's shares oscillated between $128.20 and $131.20. A total of 871,251 shares were traded which is below the daily average volume of 2.37 million. The stock has gained 59.24% in the last one month and 31.19% in the last three months, thus outperforming the S&P 500 during the respective periods. The free report on ONXX can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ONXX072413.pdf

Optimer Pharmaceuticals Inc.'s stock slipped on Tuesday, extending its losses from previous trading sessions. The company's shares fluctuated between $13.51 and $14.03 before finishing the day 0.72% lower at $13.74. A total of 1.40 million shares were traded which is above the daily average volume of 783,915. The company's shares have fallen by 7.85% in the last three trading sessions. However, the stock is trading above its 200-day moving average. A free report on OPTR can be accessed by registering at:

http://www.AAAResearchReports.com/OPTR072413.pdf

----

EDITOR NOTES: 


        
        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquiries, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports